How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,686 results for

aspirin and gastrointestinal bleeding

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Predictors of Bleeding in Patients with Symptomatic Peripheral Artery Disease: A Cohort Study Using The Health Improvement Network in the United Kingdom. (Abstract)

smoking. ORs for ICB were 0.78 (0.50-1.21), 0.40 (0.09-1.82) and 1.27 (0.47-3.47) with use of acetylsalicylic acid (ASA), clopidogrel and warfarin monotherapy, respectively, compared with non-use of such therapy. For GIB (506 cases), the OR was 1.40 (1.05-1.86) for peptic ulcer disease, 3.20 (1.81-5.64) for dual anti-platelet therapy use, 1.96 (1.46-2.64) for non-steroidal anti-inflammatory drug (NSAID) use and 1.01 (0.80-1.28) for proton pump inhibitor use. ORs for GIB were 1.78 (1.39-2.30), 2.03 (...) Predictors of Bleeding in Patients with Symptomatic Peripheral Artery Disease: A Cohort Study Using The Health Improvement Network in the United Kingdom. The purpose of this analysis was to assess potential predictors of intra-cranial bleeding (ICB) and gastrointestinal bleeding (GIB) in patients with symptomatic peripheral artery disease (PAD) in UK primary care. Patients with symptomatic PAD diagnosed from 2000 to 2010 were identified from The Health Improvement Network (THIN; N = 28,484

2018 Thrombosis and haemostasis

162. Prevention of Recurrent Ulcer Bleeding in Patients With Idiopathic Gastroduodenal Ulcer

Numbers: NRT_MISO Study First Posted: September 18, 2018 Last Update Posted: September 19, 2018 Last Verified: September 2018 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Ulcer Hemorrhage Peptic Ulcer Pathologic Processes Duodenal Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases Stomach Diseases Misoprostol Abortifacient (...) bleeding with proton pump inhibitor (PPI), yet there is a significant risk of recurrent ulcer bleeding as PPI may increase the risk of small bowel bleeding. Our preliminary data provide strong plausibility that a combination therapy of misoprostol (MISO) with a PPI reduces the recurrent ulcer bleeding as well as clinical gastrointestinal bleeding. The investigators are going to provide the definitive answer to this important clinical question through a randomised trial. Condition or disease

2018 Clinical Trials

163. SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance to Examine the Safety of Cessation of Dual Anti-Platelet Therapy in High Bleeding Risk Patients at One Month

if performed > 7 days following the index procedure or if SYNERGY stents are not used) Subject has a known allergy to: contrast (that cannot be adequately pre-medicated), the SYNERGY Stent®s system or protocol-required concomitant medications (e.g., everolimus or structurally related compounds, polymer or individual components, all P2Y12 inhibitors and aspirin) Subject previously treated at any time with intravascular brachytherapy Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding (...) Description: DAPT or Dual Antiplatelet Therapy is a combination of two medications given after a percutaneous coronary intervention (PCI) with a drug eluting stent. DAPT is used to help make the platelets in your blood slick so they don't clump or stick together. If the platelets stick together and form a blood clot in the stent it is called a stent thrombosis and will cause an immediate heart attack or MI. The medications used for DAPT are low dose Aspirin (81mg) and one of three (3) antiplatelet

2018 Clinical Trials

164. Do Patients With Inflammatory Bowel Disease Benefit from an Enhanced Recovery Pathway? (Abstract)

(63.4%), and 246 were post-ERP (36.6%). The groups did not differ in terms of age, gender, American Society of Anesthesiologist (ASA) scores, comorbidities, estimated blood loss, or ostomy construction. The post-ERP group had a significantly higher mean body mass index (BMI), more patients with CD, longer operative time, and more minimally invasive surgery (MIS; all P < 0.05). The post-ERP group had a significantly shorter LOS (6 vs 4.5 days, median), whereas mean hospital costs decreased by 15.7 (...) Do Patients With Inflammatory Bowel Disease Benefit from an Enhanced Recovery Pathway? Enhanced recovery pathways (ERPs) have been shown to reduce length of stay (LOS), complications, and costs after colorectal surgery; yet, little data exists regarding patients with inflammatory bowel disease (IBD). We hypothesized that implementation of ERP for IBD patients is associated with shorter LOS and improved economic outcomes.An IRB-approved prospective clinical database was used to identify

2019 Inflammatory Bowel Diseases

165. Aspirin and Gastric Haemorrhage Full Text available with Trip Pro

Aspirin and Gastric Haemorrhage 13269909 2003 05 01 2018 12 01 0007-1447 2 4955 1955 Dec 24 British medical journal Br Med J Aspirin and gastric haemorrhage. 1531-3 WATERSON A P AP eng Journal Article England Br Med J 0372673 0007-1447 R16CO5Y76E Aspirin OM Aspirin adverse effects Gastrointestinal Hemorrhage Hemorrhage Humans Stomach Stomach Diseases 5629:21925 ACETYLSALICYLIC ACID/injurious effects HEMORRHAGE STOMACH/hemorrhage 1955 12 24 1955 12 24 0 1 1955 12 24 0 0 ppublish 13269909

1955 British medical journal

166. Relationship between aspirin taking and gastroduodenal haemorrhage. Full Text available with Trip Pro

Relationship between aspirin taking and gastroduodenal haemorrhage. 5298015 1967 08 04 2018 11 13 0017-5749 8 3 1967 Jun Gut Gut Relationship between aspirin taking and gastroduodenal haemorrhage. 301-7 Parry D J DJ Wood P H PH eng Journal Article England Gut 2985108R 0017-5749 R16CO5Y76E Aspirin AIM IM Adolescent Adult Aged Aspirin adverse effects Child Female Gastrointestinal Hemorrhage etiology Humans Male Middle Aged Peptic Ulcer complications 1967 6 1 1967 6 1 0 1 1967 6 1 0 0 ppublish

1967 Gut

167. Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer

measures and they were discounted at an annual rate of 3.5%. Cost data: The economic analysis included the costs of chemoprevention, physicians’ visits, colonoscopy with or without polypectomy, diagnostic tests, treatment of bowel perforation and bleeding, management of adenoma and colorectal cancer (by stage), and treatment of complications (dyspepsia, gastrointestinal bleeding or ulcer, stroke, and myocardial infarction). The unit costs were from official NHS sources, such as the British National (...) -effective for the general population aged 50 to 60 years. The methods were robust and transparent and indicated the uncertainty in the results. The authors’ conclusions are valid. Type of economic evaluation Cost-effectiveness analysis, cost-utility analysis Study objective The objective was to assess the cost-effectiveness of aspirin, celecoxib, or calcium for the prevention of colorectal cancer, with a programme of screening using the faecal occult blood test (FOBT), for the general population

2012 NHS Economic Evaluation Database.

168. ACG Clinical Guideline: Management of Patients With Acute Lower Gastrointestinal Bleeding. Full Text available with Trip Pro

with hemodynamic instability may be indicative of an upper gastrointestinal (GI) bleeding source and thus warrants an upper endoscopy. In the majority of patients, colonoscopy should be the initial diagnostic procedure and should be performed within 24 h of patient presentation after adequate colon preparation. Endoscopic hemostasis therapy should be provided to patients with high-risk endoscopic stigmata of bleeding including active bleeding, non-bleeding visible vessel, or adherent clot. The endoscopic (...) -risk patients with ongoing bleeding who do not respond adequately to resuscitation and who are unlikely to tolerate bowel preparation and colonoscopy. Strategies to prevent recurrent bleeding should be considered. Nonsteroidal anti-inflammatory drug use should be avoided in patients with a history of acute lower GI bleeding, particularly if secondary to diverticulosis or angioectasia. Patients with established high-risk cardiovascular disease should not stop aspirin therapy (secondary prophylaxis

2016 American Journal of Gastroenterology

169. Comparison of Three Risk Scores to Predict Outcomes of Severe Lower Gastrointestinal Bleeding Full Text available with Trip Pro

and Education Hemostasis prognosis score, Charlson index, and American Society of Anesthesiologists (ASA) score] for the prediction of 30-day rebleeding, surgery, and death in severe LGIB.Data on consecutive patients hospitalized with severe gastrointestinal bleeding from January 2006 to October 2011 in our 2 tertiary academic referral centers were prospectively collected. Sensitivities, specificities, accuracies, and area under the receiver operator characteristic curve were computed for 3 scores (...) Comparison of Three Risk Scores to Predict Outcomes of Severe Lower Gastrointestinal Bleeding Improved medical decisions by using a score at the initial patient triage level may lead to improvements in patient management, outcomes, and resource utilization. There is no validated score for management of lower gastrointestinal bleeding (LGIB) unlike for upper gastrointestinal bleeding. The aim of our study was to compare the accuracies of 3 different prognostic scores [Center for Ulcer Research

2016 Journal of clinical gastroenterology

170. Acute Middle Gastrointestinal Bleeding Risk Associated with NSAIDs, Antithrombotic Drugs, and PPIs: A Multicenter Case-Control Study Full Text available with Trip Pro

Acute Middle Gastrointestinal Bleeding Risk Associated with NSAIDs, Antithrombotic Drugs, and PPIs: A Multicenter Case-Control Study Middle gastrointestinal bleeding (MGIB) risk has not been fully investigated due to its extremely rare occurrence and the need for multiple endoscopies to exclude upper and lower gastrointestinal bleeding. This study investigated whether MGIB is associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs), low-dose aspirin (LDA), thienopyridines (...) with acute small intestinal bleeding required blood transfusion. NSAIDs, thienopyridines, anticoagulants, and PPIs increased the risk of acute small intestinal bleeding. However, there were no significant interactions found between antithrombotic drugs and PPI use for bleeding risk.

2016 PloS one

171. Protons pump inhibitor treatment and lower gastrointestinal bleeding: Balancing risks and benefits Full Text available with Trip Pro

lower gastrointestinal bleeding (LGB). PPIs may increase both small bowel injury related to NSAIDs and low-dose aspirin treatment and the risk of LGB. Recent studies suggested that altering intestinal microbiota by PPIs may be involved in the pathogenesis of NSAID-enteropathy. An increase in LGB hospitalization rates may occur more frequently in older patients with more comorbidities and are associated with high hospital resource utilization, longer hospitalization, and increased mortality (...) Protons pump inhibitor treatment and lower gastrointestinal bleeding: Balancing risks and benefits Proton pump inhibitors (PPIs) represent a milestone in the treatment of acid-related diseases, and are the mainstay in preventing upper gastrointestinal bleeding in high-risk patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs) or low-dose aspirin. However, this beneficial effect does not extend to the lower gastrointestinal tract. PPIs do not prevent NSAID or aspirin-associated

2016 World Journal of Gastroenterology

172. Prevalence of upper gastrointestinal bleeding risk factors among the general population and osteoarthritis patients Full Text available with Trip Pro

Prevalence of upper gastrointestinal bleeding risk factors among the general population and osteoarthritis patients To assess the prevalence of possible risk factors of upper gastrointestinal bleeding (UGIB) and their age-group specific trend among the general population and osteoarthritis patients.We utilized data from the National Health Insurance Service that included claims data and results of the national health check-up program. Comorbid conditions (peptic ulcer, diabetes, liver disease (...) , chronic renal failure, and gastroesophageal reflux disease), concomitant drugs (aspirin, clopidogrel, cilostazol, non-steroidal anti-inflammatory drugs, steroid, anticoagulants, and SSRI), personal habits (smoking, and alcohol consumption) were considered as possible UGIB risk factors. We randomly imputed the prevalence of infection in the data considering the age-specific prevalence of Helicobacter pylori (H. pylori) infection in Korea. The prevalence of various UGIB risk factors and the age-group

2016 World Journal of Gastroenterology

173. Outcomes of acute upper gastrointestinal bleeding in relation to timing of endoscopy and the experience of endoscopist: a tertiary center experience Full Text available with Trip Pro

Outcomes of acute upper gastrointestinal bleeding in relation to timing of endoscopy and the experience of endoscopist: a tertiary center experience Patients with gastrointestinal bleeding admitted out of hours or at the weekends may have an excess mortality rate. The literature reports around this are conflicting.We aimed to analyze the outcomes of emergency endoscopies performed out of hours and over the weekends in our center. We retrospectively analyzed data from April 2008 to June 2012 (...) .A total of 507 'high risk' emergency gastroscopies were carried out over the study period for various indications. Patients who died within 30 days of the index procedure [22 % (114 /510)] had a significantly higher Rockall score (7.6 vs. 6.0, P < 0.0001), a higher American Society of Anesthesiologists (ASA) status (3.5 vs. 2.7, P < 0.001), and a lower systolic blood pressure (BP) at the time of the examination (94.8 vs 103, P = 0.025). These patients were significantly older (77.7 vs. 67.5 years, P

2016 Endoscopy international open

174. Efficacy Study of Thalidomide in Gastrointestinal Vascular Malformation Related Bleeding

based on a positive fecal occult blood test (FOBT) (monoclonal colloidal gold color technology) at any visit after treatment. Secondary outcomes included the changes from baseline in participants dependent on blood transfusions and transfused packed red cell units, bleeding episodes, bleeding durations, and hemoglobin levels at 12 months. Statistical significance was defined at P < 0.05. Condition or disease Intervention/treatment Phase Gastrointestinal Hemorrhage Vascular Malformation Drug (...) ClinicalTrials.gov Identifier: Other Study ID Numbers: rjyyxhk57809 First Posted: April 28, 2016 Last Update Posted: April 28, 2016 Last Verified: April 2016 Keywords provided by Zhizheng Ge, Shanghai Jiao Tong University School of Medicine: Gastrointestinal bleeding Vascular malformation Angiodysplasia Thalidomide Additional relevant MeSH terms: Layout table for MeSH terms Hemorrhage Congenital Abnormalities Gastrointestinal Hemorrhage Vascular Malformations Pathologic Processes Gastrointestinal Diseases

2016 Clinical Trials

175. Standard Endoscopic Hemostasis Versus OVESCO Severe Non-variceal UGI Hemorrhage

proton pump infusions, 27% of patients in referral hospitals with upper gastrointestinal bleeding (UGIB) from ulcers or other non-variceal UGI lesions (NVUGI) have refractory or recurrent bleeding in a recent RCT by our group. Potential risk factors for NVUGI bleeding lesions were large ulcers (≥ 15 mm), fibrotic base, Dieulafoy's lesions, anastomotic ulcers, coagulopathies, cirrhosis, severe co-morbidities, and residual arterial blood flow under stigmata after endoscopic hemostasis. Such patients (...) Numbers: OVESCO First Posted: February 28, 2017 Last Update Posted: July 6, 2018 Last Verified: July 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Keywords provided by CURE Digestive Diseases Research Center: Upper GI hemorrhage Stigmata of recent hemorrhage Diverticular Hemorrhage Ulcers Additional relevant MeSH terms: Layout table for MeSH terms Hemorrhage Gastrointestinal Hemorrhage Pathologic Processes Gastrointestinal Diseases Digestive System Diseases

2016 Clinical Trials

176. ENRICH: Early MiNimally-invasive Removal of IntraCerebral Hemorrhage (ICH)

to involve >50% of either of the lateral ventricles Primary Thalamic ICH Infratentorial intraparenchymal hemorrhage including midbrain, pontine, or cerebellar Use of anticoagulants that cannot be rapidly reversed Evidence of active bleeding involving a retroperitoneal, gastrointestinal, genitourinary, or respiratory tract site Uncorrected coagulopathy or known clotting disorder Platelet count < 75,000, International Normalized Ratio (INR) > 1.4 after correction Patients requiring long-term anti (...) Intervention/treatment Phase Intracerebral Hemorrhage Cerebral Hemorrhage Intracerebral Haemorrhage Procedure: Early Surgical Hematoma Evacuation Not Applicable Detailed Description: The ENRICH trial will compare the outcomes between early surgical intervention using the BrainPath® Approach (i.e., MIPS) and a medically managed cohort. The integrated surgical approach includes a combination of available technologies, including the FDA-cleared NICO BrainPath® for non-disruptive access and NICO Myriad®

2016 Clinical Trials

177. Letter: Naproxen (naprosyn) and gastrointestinal haemorrhage. Full Text available with Trip Pro

effects Aspirin adverse effects Blood Transfusion Female Gastritis chemically induced Gastrointestinal Hemorrhage chemically induced Hematemesis chemically induced Humans Male Melena chemically induced Methyl Ethers adverse effects Middle Aged Naphthalenes adverse effects Propionates adverse effects Salicylates adverse effects 1974 4 6 1974 4 6 0 1 1974 4 6 0 0 ppublish 4544941 PMC1610138 Ann Rheum Dis. 1974 Jan;33(1):12-9 4595271 (...) Letter: Naproxen (naprosyn) and gastrointestinal haemorrhage. 4544941 1974 06 05 2018 11 13 0007-1447 2 5909 1974 Apr 06 British medical journal Br Med J Letter: Naproxen (naprosyn) and gastrointestinal haemorrhage. 51-2 eng Comparative Study Journal Article England Br Med J 0372673 0007-1447 0 Acetanilides 0 Anti-Inflammatory Agents 0 Methyl Ethers 0 Naphthalenes 0 Propionates 0 Salicylates R16CO5Y76E Aspirin AIM IM Acetanilides adverse effects Adult Aged Anti-Inflammatory Agents adverse

1974 British medical journal

178. Epidemiology and Course of Gastrointestinal Haemorrhage in North-east Scotland Full Text available with Trip Pro

Epidemiology and Course of Gastrointestinal Haemorrhage in North-east Scotland A prospective study was made of 817 consecutive episodes of major gastrointestinal haemorrhage in patients admitted to hospital during 1967-8 from the defined population of North-East Scotland. The yearly admission rate was 116 per 100,000 population. Comparison of the data for city and country residents showed no appreciable differences. In the duodenal ulcer group there was an undue incidence of bleeding among (...) foremen and skilled workers and among those who were unmarried or widowed.Both the clinical history and the results of any previous barium meal examinations were unreliable guides to the source of the current haemorrhage. Prognosis was worse for patients who did not have a dyspeptic history and was better for those who had bled on a previous occasion. The simultaneous ingestion of alcohol and aspirin had an adverse effect on the occurrence of bleeding. Forty-seven per cent. of the patients had another

1973 British medical journal

179. Letter: Minimizing the incidence of ASA-induced occult gastrointestinal bleeding. Full Text available with Trip Pro

Letter: Minimizing the incidence of ASA-induced occult gastrointestinal bleeding. 1083282 1976 07 06 2018 11 13 0008-4409 114 6 1976 Mar 20 Canadian Medical Association journal Can Med Assoc J Letter: Minimizing the incidence of ASA-induced occult gastrointestinal bleeding. 496, 498 Madan P L PL eng Journal Article Canada Can Med Assoc J 0414110 0008-4409 R16CO5Y76E Aspirin AIM IM Aspirin adverse effects Gastrointestinal Hemorrhage chemically induced prevention & control Humans 1976 3 20 1976 3

1976 Canadian Medical Association Journal

180. Association of aspirin use with major bleeding in patients with and without diabetes. Full Text available with Trip Pro

million citizens in 12 local health authorities in Puglia, Italy. Individuals with new prescriptions for low-dose aspirin (≤300 mg) were identified during the index period from January 1, 2003, to December 31, 2008, and were propensity-matched on a 1-to-1 basis with individuals who did not take aspirin during this period.Hospitalizations for major gastrointestinal bleeding or cerebral hemorrhage occurring after the initiation of antiplatelet therapy.There were 186,425 individuals being treated (...) Association of aspirin use with major bleeding in patients with and without diabetes. The benefit of aspirin for the primary prevention of cardiovascular events is relatively small for individuals with and without diabetes. This benefit could easily be offset by the risk of hemorrhage.To determine the incidence of major gastrointestinal and intracranial bleeding episodes in individuals with and without diabetes taking aspirin.A population-based cohort study, using administrative data from 4.1

2012 JAMA

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>